Regulatory News :
The Combined Shareholders’ Meeting of Ipsen S.A. (Paris:IPN) (Euronext: IPN ; ADR: IPSEY), chaired by Marc de Garidel, Chairman and Chief Executive Officer, was held today, in the presence of the members of the Board of Directors and the Group General Management.
The Shareholders’ Meeting approved all the resolutions submitted by the Board of Directors and in particular the distribution of €0.80 dividend per share to be paid on 10 June 2013 (ex-dividend date 5 June 2013) and the renewal of the terms of office as Directors of Mr Antoine Flochel and Mr Gérard Hauser as well as the appointment of Mrs Martha Crawford as Director.
During the Meeting, Marc de Garidel, Christel Bories, Deputy Chief Executive Officer and Susheel Surpal, Executive Vice President, Chief Financial Officer, presented, in particular, the major events and financial results for 2012 as well as the 2013 outlook and 2013 first quarter sales.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology / Dysport®, endocrinology / Somatuline® and uro-oncology / Decapeptyl®. Moreover, the Group has an active policy of partnerships. Ipsen´s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totaled close to €250 million, representing more than 20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
